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Gadolinium and 
nephrogenic systemic 
fibrosis
A rare and puzzling syndrome called 
nephrogenic systemic fi brosis causes the 
skin to become hardened and thickened 
in a manner similar to that of infi ltrative 
diseases of the skin.  Th ere is now good 
evidence of an association between the 
use of gadolinium in contrast media and 
development of the skin lesion. Skin 
biopsies show an excessive presence of 
fi broblasts and large accumulation of 
collagen and mucin. Gadolinium, a metal 
from the lanthanide series, is thought to 
be a safe reagent, even in patients with 
renal failure. Recent studies have shown 
that in such patients, gadolinium is 
deposited in the skin and, surprisingly, is 
associated with deposition of iron as well. 
In this issue, Grobner and Prischl review 
the literature that has accumulated 
since their original publication of 
the association between this obscure 
skin disease and gadolinium. Th ey 
also speculate about the potential 
mechanism by which deposition of 
gadolinium could lead to nephrogenic 
systemic fi brosis. See page 260.
T-cell polarization in 
a mouse model of IgA 
nephropathy
Despite the prevalence of IgA 
nephropathy, very little insight exists 
at present into its pathogenesis. But 
a recent study suggests that T cells 
might be involved; a patient with 
IgA nephropathy and leukemia 
who underwent bone marrow 
transplantation had remission of the 
leukemia and nephropathy (Sakai, O.
et al. Nephrology 1997; 3: 2–3). 
T-helper (Th ) cells are present in two 
forms, Th 1 and Th 2, each of which 
produces a specifi c repertoire of 
cytokines.
To investigate this matter, Suzuki 
et al. studied a mouse of the strain 
ddY, which developed spontaneous 
glomerular injury mimicking 
human IgA nephropathy. When the 
authors fractionated the T cells in 
ddY mice, they found that mice with 
newly developed IgA nephropathy 
demonstrated strong polarization 
toward Th 1, whereas those with 
quiescent disease were Th 2 polarized. 
Serum levels of IgA/IgG2a immune 
complex signifi cantly correlated with 
the severity of the glomerular lesions. 
Th e authors then irradiated these mice 
and transplanted bone marrow cells 
from the ddY mice into irradiated 
similar ddY mice, or into other mouse 
strains that were prone to Th 1 or Th 2 
diseases. Bone marrow taken from 
mice with IgA nephropathy produced 
IgA nephropathy with Th 1 polarization 
in recipient mice with quiescent 
disease, while transplantation from the 
quiescent mice into mice with newly 
developed IgA nephropathy ablated 
glomerular injury and mesangial IgA/
IgG deposition. Th ese studies provide 
strong evidence that bone marrow-
derived cells, presumably those 
that produce IgA, may initiate IgA 
nephropathy. Also, Th 1 T cells or their 
cytokines might be involved in the 
development of glomerular injury aft er 
the deposition of IgA. See page 319. 
N-acetylcysteine 
and gentamicin 
ototoxicity
Deafness following the use of 
gentamicin is a serious and permanent 
side eff ect. Like in many drug 
toxicities, some evidence shows that 
gentamicin activates oxidative stress, 
causing both nephrotoxicity and 
deafness. In a controlled trial, Feldman 
et al. treated hemodialysis patients 
scheduled to receive gentamicin with 
N-acetylcysteine, a potent antioxidant. 
Patients in the control group received 
aminoglycoside alone. Both groups 
had their hearing tested by standard 
audiometric tests before gentamicin 
and 1 and 6 weeks aft er the completion 
of the antibiotic course, which lasted 
15 days on average. Th e hemodialysis 
patients had renal failure, and hence 
their doses of gentamicin were 
adjusted. Despite this fact, a signifi cant 
number of those in the control group 
receiving aminoglycoside developed 
signifi cant hearing loss as compared 
with those receiving N-acetylcysteine. 
Several patients in the control 
group had bilateral hearing loss. 
N-acetylcysteine most signifi cantly 
protected the loss of hearing of high-
frequency tones. Th ese results provide 
both an interesting mechanistic insight 
and a potential therapeutic approach 
to the serious problem of drug toxicity. 
See page 359.
